L
Latha Velayudhan
Researcher at King's College London
Publications - 83
Citations - 2638
Latha Velayudhan is an academic researcher from King's College London. The author has contributed to research in topics: Medicine & Dementia. The author has an hindex of 21, co-authored 64 publications receiving 1772 citations. Previous affiliations of Latha Velayudhan include South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease
Madhav Thambisetty,Andrew Simmons,Latha Velayudhan,Abdul Hye,James Campbell,Yi Zhang,Lars-Olof Wahlund,Eric Westman,Anna Kinsey,Andreas Güntert,Petroula Proitsi,John Powell,Mirsada Causevic,Richard Killick,Katie Lunnon,Steven Lynham,Martin Broadstock,Fahd Choudhry,David R. Howlett,Robert J. Williams,Sally I. Sharp,Cathy Mitchelmore,Catherine Tunnard,Rufina Leung,Catherine Foy,Darragh O'Brien,Gerome Breen,Simon J. Furney,Malcolm Ward,Iwona Kłoszewska,Patrizia Mecocci,Hilkka Soininen,Magda Tsolaki,Bruno Vellas,Angela Hodges,Declan G. Murphy,Sue Parkins,Jill C. Richardson,Susan M. Resnick,Luigi Ferrucci,Dean F. Wong,Yun Zhou,Sebastian Muehlboeck,Alan C. Evans,Paul T. Francis,Christian Spenger,Simon Lovestone +46 more
TL;DR: These results demonstrate an important role of clusterin in the pathogenesis of AD and suggest that alterations in amyloid chaperone proteins may be a biologically relevant peripheral signature of AD.
Journal ArticleDOI
A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease.
Douglas P Wightman,Iris E. Jansen,Jeanne E. Savage,Alexey A. Shadrin,Shahram Bahrami,Shahram Bahrami,Dominic Holland,Arvid Rongve,Sigrid Børte,Sigrid Børte,Sigrid Børte,Bendik S. Winsvold,Bendik S. Winsvold,Ole Kristian Drange,Amy E Martinsen,Amy E Martinsen,Amy E Martinsen,Anne Heidi Skogholt,Cristen J. Willer,Geir Bråthen,Ingunn Bosnes,Ingunn Bosnes,Jonas B. Nielsen,Jonas B. Nielsen,Jonas B. Nielsen,Lars G. Fritsche,Laurent F. Thomas,Linda M. Pedersen,Maiken Elvestad Gabrielsen,Marianne Bakke Johnsen,Marianne Bakke Johnsen,Marianne Bakke Johnsen,Tore Wergeland Meisingset,Wei Zhou,Wei Zhou,Petroula Proitsi,Angela Hodges,Richard Dobson,Latha Velayudhan,Karl Heilbron,Adam Auton,Julia M. Sealock,Lea K. Davis,Nancy L. Pedersen,Chandra A. Reynolds,Ida K. Karlsson,Ida K. Karlsson,Sigurdur H. Magnusson,Hreinn Stefansson,Steinunn Thordardottir,Palmi V. Jonsson,Jon Snaedal,Anna Zettergren,Ingmar Skoog,Ingmar Skoog,Silke Kern,Silke Kern,Margda Waern,Margda Waern,Henrik Zetterberg,Kaj Blennow,Kaj Blennow,Eystein Stordal,Eystein Stordal,Kristian Hveem,John-Anker Zwart,John-Anker Zwart,John-Anker Zwart,Lavinia Athanasiu,Lavinia Athanasiu,Per Selnes,Ingvild Saltvedt,Sigrid Botne Sando,Ingun Ulstein,Srdjan Djurovic,Srdjan Djurovic,Tormod Fladby,Tormod Fladby,Dag Aarsland,Dag Aarsland,Geir Selbæk,Geir Selbæk,Stephan Ripke,Stephan Ripke,Stephan Ripke,Kari Stefansson,Ole A. Andreassen,Ole A. Andreassen,Danielle Posthuma,Danielle Posthuma +89 more
TL;DR: This paper identified microglia, immune cells and protein catabolism as relevant genes for late-onset Alzheimer's disease, while identifying and prioritizing previously unidentified genes of potential interest.
Journal ArticleDOI
Review of brief cognitive tests for patients with suspected dementia.
Latha Velayudhan,Seungho Ryu,Malgorzata (Gosia) Raczek,Michael Philpot,James Lindesay,Matthew Critchfield,Gill Livingston +6 more
TL;DR: Tests such as Test for Early Detection of Dementia, Test Your Memory, Cognitive Assessment Screening Test (CAST) and the recently developed ACE-III show promise but need validation in different settings, populations, and dementia subtypes.
Journal ArticleDOI
A feasibility and tolerability study of lithium in Alzheimer's disease
Alastair Macdonald,Kate Briggs,Michaela Poppe,Andrea Higgins,Latha Velayudhan,Simon Lovestone +5 more
TL;DR: To assess the safety and feasibility of prescribing long term lithium to elderly people with mild to moderate Alzheimer's disease (AD), a clinical trial is conducted at the University of California, Berkeley.
Journal ArticleDOI
A multicentre validation study of the diagnostic value of plasma neurofilament light.
Nicholas J. Ashton,Shorena Janelidze,Ahmad Al Khleifat,Antoine Leuzy,Emma L. van der Ende,Thomas K. Karikari,Andrea Lessa Benedet,Andrea Lessa Benedet,Tharick A. Pascoal,Tharick A. Pascoal,A. Lleo,Lucilla Parnetti,Daniela Galimberti,Laura Bonanni,Andrea Pilotto,Alessandro Padovani,Jan Lycke,Jan Lycke,Lenka Novakova,Lenka Novakova,Markus Axelsson,Markus Axelsson,Latha Velayudhan,Latha Velayudhan,Gil D. Rabinovici,Bruce L. Miller,Carmine M. Pariante,Naghmeh Nikkheslat,Susan M. Resnick,Madhav Thambisetty,Michael Schöll,Michael Schöll,Gorka Fernández-Eulate,Francisco Javier Gil-Bea,Adolfo López de Munain,Ammar Al-Chalabi,Ammar Al-Chalabi,Pedro Rosa-Neto,Pedro Rosa-Neto,Andre Strydom,Andre Strydom,Per Svenningsson,Per Svenningsson,Erik Stomrud,Alexander Santillo,Dag Aarsland,Dag Aarsland,Dag Aarsland,John C. van Swieten,Sebastian Palmqvist,Henrik Zetterberg,Kaj Blennow,Kaj Blennow,Abdul Hye,Abdul Hye,Abdul Hye,Oskar Hansson +56 more
TL;DR: In this article, increased cerebrospinal fluid neurofilament light (NfL) is used as a marker of neurodegeneration in 13 neuro-degenerative disorders, Down syndrome, depression and cognitively unimpaired controls from two multicenter cohorts.